Transforming ovarian cancer care by targeting minimal residual disease

Jazaeri, Amir A; Grisham, Rachel; Knisely, Anne; Spranger, Stefani; Zamarin, Dmitriy; Hillman, R Tyler; Lawson, Barrett C; Burns, Kathleen H; Lee, Sanghoon; Westin, Shannon N; Moiso, Enrico; Williams, Marc J; Bardhan, Neelkanth M; Pisanic, Thomas; Matulonis, Ursula; Weigelt, Britta; Shih, IeMing; Konstantinopoulos, Panagiotis A; Gaillard, Stephanie; Wang, Linghua; Aghajanian, Carol; D’Andrea, Alan D; Hammond, Paula; Shah, Sohrab; Wucherpfennig, Kai W; Lu, Karen H

Author(s)

Jazaeri, Amir A; Grisham, Rachel; Knisely, Anne; Spranger, Stefani; Zamarin, Dmitriy; ... Show more

DownloadAccepted version (829.2Kb)

Open Access Policy

Terms of use

Creative Commons Attribution-Noncommercial-ShareAlike http://creativecommons.org/licenses/by-nc-sa/4.0/

Metadata

Show full item record

Abstract

Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences.

Date issued

2023-11-10

URI

https://hdl.handle.net/1721.1/160689

Department

Koch Institute for Integrative Cancer Research at MIT

Journal

Med

Publisher

Elsevier BV

Citation

Jazaeri, Amir A, Grisham, Rachel, Knisely, Anne, Spranger, Stefani, Zamarin, Dmitriy et al. 2023. "Transforming ovarian cancer care by targeting minimal residual disease." Med, 4 (11).

Version: Author's final manuscript

Collections

MIT Open Access Articles